EVMN vs EPRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EPRX Captures Institutional Edge (2โ1 Pillars ยท 5โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) driven by superior Growth & Margin, Momentum & Technical while EVMN counters with relative strength in Options & Structure. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EPRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against EPRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVMN | EPRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $315.5M | $548.2M | Larger Scale | EPRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -69.5% | -56.4% | Higher ROE | EPRX |
| 52-Week Range Position Momentum | 8% ($5โ$33) | 46% ($6โ$9) | Stronger Trend | EPRX |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 118% Vol | 1.70ฮฒ ยท 76% Vol | Lower Realized Risk | EPRX |
| Unified Institutional Score Composite Signal | 30.0 / 100 (SELL) | 34.1 / 100 (SELL) | Higher Composite | EPRX |